Jeffrey M Gross insider trades: Angiotech Pharmaceuticals (ANPI) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Jeffrey reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Mar 26, 2010 | ANPI | ↑ Buy | 9,000 | $1.11 | $10K | Direct | Mar 26, 2010 (0d) |
| Aug 27, 2009 | ANPI | ↑ Buy | 6,000 | $1.68 | $10K | Direct | Aug 31, 2009 (4d) |
| Aug 14, 2009 | ANPI | ↑ Buy | 3,500 | $1.77 | $6K | Direct | Aug 14, 2009 (0d) |
| Jun 22, 2009 | ANPI | ↑ Buy | 20,000 | $1.77 | $35K | Direct | Jun 23, 2009 (1d) |
| Jun 17, 2009 | ANPI | ↑ Buy | 12,500 | $1.85 | $23K | Direct | Jun 18, 2009 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Jeffrey M Gross's insider trades
Jeffrey M Gross is SVP, Research & Development at Angiotech Pharmaceuticals (ANPI). Since Jun 17, 2009, Jeffrey has reported 5 open-market purchases worth $85K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (3 filings), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ANPI insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.